Status of p53 and WAF1/CIP1 in anogenital lesions harboring human papillomavirus and human immunodeficiency virus (Meeting abstract).

Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Status of p53 and WAF1/CIP1 in anogenital lesions harboring human papillomavirus and human immunodeficiency virus (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 38:A1063 1997. Unique Identifier : AIDSLINE ICDB/98638063
Arany I; Yen A; Tyring SK; Department of Microbiology and Immunology, University of Texas; Medical Branch, Galveston, TX

Abstract: Human papillomaviruses (HPVs) express various gene products, such as E6 protein which complexes with the p53 tumor suppressor protein and therefore diminishes p53-related regulatory mechanisms. Furthermore, HIV infection is believed to activate latent HPV infection and transcription. Accordingly, we carried out experiments on biopsies originated from condylomas ('low risk' HPVs), HIV-positive condylomas (infection with multiple 'low risk' and 'high risk' HPVs) and anogenital squamous cell carcinomas (SCCs, 'high risk' HPV infection). Using reverse-transcription PCR (RT-PCR) and Western immunoblotting, mRNA and protein levels of p53 and genes regulated by p53, such as mdm2 and WAF1/CIP1 were determined. We found that the presence of HPV can diminish p53 and increase WAF1/CIP1 and mdm2 protein levels. There were no significant differences in this regulation between 'low risk' and 'high risk' lesions. Our data suggest that these HPV-mediated cellular effects are not type-specific, and they might be part of a viral-cell interaction or represent a cellular defense mechanism against the virus. However, HIV-seropositivity renders HPV lesions containing both 'low risk' and 'high risk' significantly different. This may be due to the alteration of HPV-controlling cellular pathways by HIV tat and/or activation of cellular pathways different from HIV-negative counterparts. Either possibility has great interest and needs further verification.

Keywords: Anus Neoplasms/*VIROLOGY Carcinoma, Squamous Cell/*VIROLOGY Cyclins/*GENETICS/METABOLISM Genes, p53/GENETICS Genital Neoplasms, Female/*VIROLOGY HIV-1/*GENETICS Human Papillomavirus, Human/*GENETICS Protein p53/METABOLISM Proto-Oncogene Proteins/GENETICS/METABOLISM ABSTRACT
980228
M9820763

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .